Phathom Pharmaceuticals, Inc.
PHATHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Phathom Pharmaceuticals, Inc. focuses on Biotechnology services and products. Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. The company carries a $872.5M market cap, placing it firmly in the small-cap category. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
Market Cap
$872.5M
Beta
0.49
P/E (TTM)
—
P/E (Fwd)
7.60
EPS (TTM)
$-2.08
EPS (Fwd)
$1.44
ROE
—
ROA
-20.2%
Cash
$180.9M
Total Debt
$547.2M
Free CF
-$77.5M
52W Change
37.6%
Annual Financials
Cash vs Debt
On the balance sheet, PHAT has $180.9M in cash with $547.2M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$77.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet.
The relatively low beta of 0.49 suggests PHAT is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Phathom Pharmaceuticals, Inc.'s trajectory.